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as X-ray, computed tomography, and ultrasonography; however, these methods are not suitable for early diagnosis because they can detect only EPS in an advanced stage [2, 3, 6] . C-reactive protein (CRP) and interleukin-6 (IL-6) are often used as biochemical markers for inflammation [2, 6, 14, 15] . However, since their levels also increase during infectious peritonitis, they are inadequate to be used as definitive diagnostic markers that can differentiate EPS from infectious peritonitis [14] . As mentioned previously, corticosteroids and immunosuppressive agents have been employed as effective initial therapies for EPS [2- 4, 6] ; however these drugs, compromise the immune system with the risk of aggravating symptoms when administered to patients with infectious peritonitis. Therefore, a method can differentiate EPS from infectious peritonitis is required for the early diagnosis of EPS. To perform PD safely, it is important to monitor peritoneal injury that may progress to EPS and diagnose EPS at an early stage; it is then necessary to prevent peritoneal injury from developing into severe EPS. During tissue injury, such as sclerosis or fibrosis, tissue destruction and excessive remodeling occur. In such events, matrix metalloproteinases (MMPs) degrade components of the extracellular matrix (ECM) and play significant roles in regulating angiogenesis, epithelial to mesenchymal transition, and migration of cells that promote fibroplasias or inflammation. MMP-1, an interstitial collagenase, degrades types I, II, III, VII, and X collagen. MMP-2, a gelatinase, degrades gelatin, type IV collagen, fibronectin, laminin, proteoglycan, and elastin. MMP-3, a stromelysin, degrades proteoglycan, gelatin, fibronectin, laminin, elastin, and type IV collagen. MMP-9, a gelatinase, degrades gelatin, type IV collagen, proteoglycans, elastin, and entactin. Membrane-type MMP-1 (MT1-MMP) contains a C-terminal transmembrane domain that anchors to the plasma membrane and cleaves proMMP-2 to produce its active form on the cell surface. Tissue inhibitors of MMP (TIMPs) inhibit ECM degradation by MMPs and play important roles in the proteolytic/antiproteolytic balance. TIMP-2 inhibits the activity of MT-MMPs, but TIMP-1 does not. MMP expression is enhanced in various tissues during inflammation, fibrosis and sclerosis. Increased serum levels of MMP-1 and MMP-3 in rheumatoid arthritis [16] , MMP-1, MMP-8, and MMP-9 in cystic fibrosis [17] , MMP-9 in chronic obstructive pulmonary disease [18] , MMP-2, MMP-9, and TIMP-1 in acute coronary syndrome [19] , MMP-9 and TIMP-1 in aortic sclerosis [20] , MMP-2 in liver cirrhosis [21] , MMP-2 and TIMP-1 in hepatic fibrosis [22] , and MMP-2 in chronic kidney disease [23, 24] suggest a relationship between MMP levels and pathology of tissue injury.
Production of MMP-2 in animal models of peritoneal injury
MMP-2 production increases in animal models of peritoneal injury induced by stimuli such as antiseptics, exogenous materials, and GDPs. In rodent models of peritoneal injury, the development of EPS was analyzed by injecting the antiseptic chlorhexidine gluconate into the peritoneal cavity to induce inflammation [7] [8] [9] [10] [11] . In this model, MMP-2 levels in the peritoneal effluent and MMP-2 gene expression in the peritoneum correlated with changes in thickness of the peritoneum, inflammation, D/D0 glucose levels, and net ultrafiltration. In another model, peritoneal injury was induced by injecting talc, an exogenous material, into the peritoneal cavity. MMP-2 levels in the peritoneal effluent and MMP-2 gene expression in the peritoneum increased with the development of peritoneal injury [7] . GDPs are generated in PD solutions during heat sterilization and storage, and contribute to the bioincompatibility of conventional PD solutions. MMP-2 levels in the peritoneal effluent increased in models of peritoneal injury induced by methylglyoxal (MGO) or formaldehyde, both extremely toxic GDPs [12, 13] . In models of peritoneal injury induced by chlorhexidine gluconate and MGO, abdominal cocoons were often formed, while in models induced by talc and formaldehyde, adhesions of the peritoneum were observed [7-9, 11, 12] . In many animal models of peritoneal injury, MMP-2 levels in the peritoneal effluent correlated with changes in inflammation, thickness of the peritoneum, D/D0 glucose levels, and net ultrafiltration. Thus, peritoneal injury is caused by increased MMP-2 induced by various stimuli, such as antiseptics, exogenous materials, and GDPs in the PD solution. Therefore, MMP-2 may play an important role in the development of peritoneal injury leading to EPS.
MMPs as peritoneal injury markers in clinical diagnosis
Results of the peritoneal equilibration test (PET) performed clinically have shown that MMP-2, -3, and TIMP-1 levels in the peritoneal effluent correlate with peritoneal injury (Figure 1 ) [25, 26] . PET is the method most frequently used to estimate PD efficiency and peritoneal injury [2, 27] . MMP-3 levels are influenced by gender and etiology of end-stage renal disease [26] and TIMP-1 expression is known to be induced by various factors, such as IL-1, tumor necrosis factor-, and transforming growth factor- [23] ; however, MMP-2 is usually expressed constitutively. MMP-3 and TIMP-1 may therefore be more easily affected by various factors than MMP-2. The measured D/S ratios of MMP-3 were nearly equal to the predicted D/S ratios when MMP-3 was transported only from the circulation [26] . This result suggests that most MMP-3 in the peritoneal effluent may be transported from the circulation. In contrast, the measured D/S ratios of MMP-2 and TIMP-1 were significantly higher than those predicted [26] . In addition, the correlation coefficient between the drainage levels of MMP-2 and TIMP-1 was higher than that between the drainage levels of MMP-2 and MMP-3 [26] . The difference between the measured D/S ratio and the predicted ratio may be attributable to the local production of MMP-2 and TIMP-1 in the peritoneal tissue along with their transport from the circulation [28] . In addition, MMP-1 and TIMP-2 were not detected in the peritoneal effluent of most patients. Therefore, MMP-1 and TIMP-2 are unsuitable as markers for determining the extent of peritoneal injury. These results suggest that MMP-2 may be a more useful marker of peritoneal injury with increased solute transport than other MMPs or TIMPs. IL-6, hyaluronic acid, and cancer antigen (CA) 125 are often used as markers of peritoneal injury [2, 29] . In the study by Kaku et al., although the sample size was not sufficient for a statistically significant relationship, the correlation coefficient between the peritoneal solute transport rate and MMP-2 levels was higher than that for IL-6, hyaluronic acid, or CA125 [15] . MMP-2 and/or MMP-9 degrade the endothelial basal lamina and increase vascular permeability [30] . Swann et al. have also reported that an increase in the permeability of the b l o o d -b r a i n b a r r i e r i s a s s o c i a t e d w i t h a n increase in MMP levels, which digests the endothelial basal lamina that forms the barrier [31] . In PD, the microvascular wall and probably the interstitial tissue are the main barriers for peritoneal fluid and solute transport. MMP-2 digests type IV collagen and laminin, which are the main basement membrane components of the microvascular wall and the mesothelial layer. Thus, injury to the basement membrane by MMP-2 may result in fast solute transport rates. Giebel et al. have reported that elevated MMP-2 or MMP-9 expression in the retina may facilitate an increase in vascular permeability by degrading occludin, the tight junction protein of endothelial or epithelial cells [32] . Osada the blood vessels in the peritoneal tissues from long-term PD patients [33] . In PD, destruction of the tight junction of endothelial cells by MMP-2 may result in hyperpermeability of the peritoneum. From these studies, it is apparent that MMP-2 may directly increase the permeability of the peritoneum by destruction of the basement membrane and tight junction of endothelial cells. A multi-center clinical study and a case report revealed markedly increased MMP-2 levels in peritoneal effluents of patients with moderate peritoneal injury with ascites [2, 25, 34] . In addition, EPS was shown to develop in more than half the patients having MMP-2 levels of more than 600 ng/ml, although half of the patients had been treated with steroids [26] . On the other hand, MMP-2 levels in the effluents of patients with EPS tended to be lower than those of patients with moderate peritoneal injury [26] . In advance-stage of EPS, the inflammation is weak and then MMP-2 levels in the effluents may be decreased. These findings suggest that a change in MMP-2 levels may be used as indicator of peritoneal injury or progression to EPS. MMP-9 is hardly detected in the peritoneal effluent of patients without infectious peritonitis. However, in patients with infectious peritonitis, MMP-9 levels in the peritoneal effluent increased markedly with a slight increase in MMP-2 levels [25, 35, 36] . These findings suggest that peritoneal injury that may lead to EPS can be clearly distinguished from infectious peritonitis by analyzing MMP-2 and MMP-9 levels in the peritoneal effluent (Figure 2 ). Many biomarkers, such as IL-6 and CRP, increase during peritoneal injury and infectious peritonitis. Therefore, MMP-2 may be a useful indicator for peritoneal injury that can differentiate from infectious peritonitis. Minami et al. investigated the correlations between 2 -microglobulin ( 2 MG) and peritoneal injury biomarkers (e.g. hyaluronic acid, IL-6, MMP-2) in the peritoneal effluent obtained from a 7.5% icodextrin-based PD solution (ICO effluent) [37] . 2 MG, hyaluronic acid, and MMP-2 levels in the ICO effluent were significantly higher than those in the 2.27% glucosebased PD solution effluent. There was a trend toward higher IL-6 levels in the ICO effluent, although no significant differences were seen. There were positive correlations between the levels of various biomarkers and 2 MG. Those authors proposed that subclinical injury of the peritoneum by ICO treatment may accelerate peritoneal permeability to increase 2 MG in the effluent. Nishina et al. have reported that MMP-2 levels decreased in the peritoneal effluent and peritoneal function improved when conventional solutions (acidic pH and containing high levels of GDPs) were replaced with new PD solutions (neutral pH and containing low levels of GDPs) in high-transporter patients undergoing PD [38] . Thus MMPs are possible markers of peritoneal injury that can differentiate from infectious peritonitis. A diagnostic method using peritoneal effluents enables easy sampling, is noninvasive, and is not painful for patients. An MMP-9 test kit has been developed to diagnose infectious peritonitis. This kit consists of an anti-MMP-9 antibody conjugated to a colloidal dye designed to detect MMP-9 in a nitrocellulose membrane dipstick assay based on immunochromatography [36, 39] . The diagnosis can be successfully completed within 10 min. If such a test kit were developed for MMP-2, peritoneal injury could be monitored easily and rapidly at home.
Production of MMP-2 in the peritoneum
MMP-2 in the peritoneal tissue and effluent is considered to be primarily derived from activated cells in the peritoneum. Gene expression analysis and/or immunohistochemistry analysis revealed that MMP-2, MT1-MMP, and TIMP-2 are produced in the peritoneal tissue [7] [8] [9] [10] [11] [12] [13] 25] . MMP-2 is produced by peritoneal cells, such as macrophages, mesenchymal cells, endothelial cells, and mesothelial cells ( Figures 3 and 4 , Table) . These peritoneal cells are activated by various stimuli, such as infectious peritonitis; exogenous materials like particulates; antiseptics; advanced glycation products; and GDPs and also the pH of the PD solution. These activated cells produce various cytokines, growth factors, and other mediators that induce peritoneal injury. Macrophages may infiltrate or migrate into the peritoneum while ECM is being degraded by MMP-2 produced by these cells [8, 12] . In cultured human mesothelial cells, the production of MMP-2 is upregulated by transforming growth factor-and is decreased by thrombin [40] [41] [42] . Activated mesothelial cells transform to mesenchymal cells and then the epithelial-to-mesenchymal transition of mesothelial cells subsequently induces MMP-2 production [13, 43] . Transformed mesothelial cells may invade the peritoneum while ECM is being digested by MMP-2 and upregulates the production of vascular endothelial growth factor that enhances angiogenesis, nitric oxide synthesis, and vascular permeability [25, 26] . [44] , which may explain why drainage levels of MMP-2 reflects the peritoneal transport ratio. Activated mesenchymal cells, such as myofibroblasts or fibroblasts, synthesize ECM proteins or migrate during the disassemble of ECM of the peritoneum by MMP-2 or other proteinases [8] [9] [10] [11] [12] 33] . Presence of excessive ECM proteins, such as collagen, leads to peritoneal fibrosis with peritoneal thickening and promotes the production of MMP-2 by myofibroblasts [9] . In addition, neomicrovascularization may occur while ECM is being degraded by MMP-2 produced by activated endothelial cells in the microvasculature [10, 12, 33] . According to the results of D/S ratio analysis, most MMP-2 in the peritoneal effluent is not transported from the circulation [26] . The measured D/S ratios of MMP-2 were higher than those predicted when MMP-2 was transported from the circulation only by diffusion. In summary, MMP-2 is produced by various peritoneal cells activated by a variety of stimuli. Because MMP-2 is produced primarily in the peritoneum, its drainage levels may indicate the condition of peritoneal injury.
Protection from peritoneal injury by inhibition of MMP-2
Peritoneal injury may be avoided by drugs that inhibit MMP-2 activity. Ro et al. have reported that the MMP inhibitor ONO-4817 controlled angiogenesis, infiltration of macrophage, and peritoneal fibrosis in rat models of peritoneal sclerosis [10] , which suggests the possibility of protection from peritoneal injury by inhibition of MMP-2 activities. Angiotensin-converting enzyme (ACE) inhibitors have been shown to have inhibitory effects on MMP-2 activity [45, 46] . Yamamoto et al. have proposed a mechanism for the inhibitory specificity of ACE inhibitors against MMP-2 using three-dimensional models of the MMP-2-ACE inhibitor complex. Furthermore, these authors showed that ACE inhibitors directly inhibited MMP-2 activity in the peritoneal effluent from patients on PD [47] . In experimental animal models, use of ACE inhibitors protected the animals from peritoneal injury with fibrosis thickening and functional decline, such as increased solute transport [48] [49] [50] . Sampimon et al. have reported the clinical possibility of a protective effect of ACE inhibitors on the development of EPS although it did not achieve statistical significance [51] . Thus, randomized controlled trials are needed to determine the level of protection gained against peritoneal injury using drugs, such as ACE inhibitors, that have an inhibitory effect on MMP-2 activity.
Conclusions
MMPs play critical roles in peritoneal injury. To perform PD safely, it is important to clarify the mechanisms by which MMPs cause peritoneal injury. MMP levels in the peritoneal effluent may be used as markers of peritoneal injury that can differentiate early EPS from infectious peritonitis. In addition, patients undergoing PD may be protected against peritoneal injury by controlling MMP activities. Future studies should examine the changes in MMP-2 levels with regard to progression of peritoneal injury to EPS and confirm the effects of MMPs inhibitors in controlling peritoneal injury 
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